UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term study of a quadrivalent human papillomavirus vaccine

Pediatrics (Evanston), 2014-09, Vol.134 (3), p.e657-e665

2014

Volltextzugriff (PDF)

Indications and efficacy of the human papillomavirus vaccine

Current treatment options in oncology, 2007-12, Vol.8 (6), p.393-401

2007

Volltextzugriff (PDF)

Prophylactic HPV vaccination: past, present, and future

Epidemiology and infection, 2016-02, Vol.144 (3), p.449-468

2016

Volltextzugriff (PDF)

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

The Lancet (British edition), 2009-06, Vol.373 (9679), p.1949-1957

2009

Volltextzugriff (PDF)

The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study

BMC cancer, 2020-11, Vol.20 (1), p.1056-1056, Article 1056

2020

Volltextzugriff (PDF)

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1–Infected Women

Clinical infectious diseases, 2014-07, Vol.59 (1), p.127-135

2014

Volltextzugriff (PDF)

Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children

Vaccine, 2016-08, Vol.34 (36), p.4343-4350

2016

Volltextzugriff (PDF)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine

PloS one, 2015-10, Vol.10 (10), p.e0140926-e0140926

2015

Volltextzugriff (PDF)

Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States

Vaccine, 2023-03, Vol.41 (11), p.1826-1833

2023

Volltextzugriff (PDF)

Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System

American journal of epidemiology, 2018-06, Vol.187 (6), p.1269-1276

2018

Volltextzugriff (PDF)

The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus

Vaccine, 2017-05, Vol.35 (20), p.2642-2646

2017

Volltextzugriff (PDF)

Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status

Vaccine, 2018-11, Vol.36 (46), p.7025-7032

2018

Volltextzugriff (PDF)

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

Journal of internal medicine, 2012-02, Vol.271 (2), p.193-203

2012

Volltextzugriff (PDF)

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

JAMA : the journal of the American Medical Association, 2009-08, Vol.302 (7), p.750

2009

Volltextzugriff (PDF)

Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016)

Revista do Instituto de Medicina Tropical de São Paulo, 2019-01, Vol.61, p.e43-8

2019

Volltextzugriff (PDF)

Safety of quadrivalent human papillomavirus vaccine (Gardasil® ) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013

Vaccine, 2015-01, Vol.33 (4), p.519-522

2015

Volltextzugriff (PDF)

FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)

MMWR. Morbidity and mortality weekly report, 2010-05, Vol.59 (20), p.626-629

Centers for Disease Control and Prevention (CDC)

2010

Volltextzugriff (PDF)

FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)

MMWR. Morbidity and mortality weekly report, 2010-05, Vol.59 (20), p.630-632

Centers for Disease Control and Prevention (CDC)

2010

Volltextzugriff (PDF)

Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011

Vaccine, 2016-01, Vol.34 (1), p.167-171

2016

Volltextzugriff (PDF)

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts

Drugs (New York, N.Y.), 2014-07, Vol.74 (11), p.1253-1283

McCormack, Paul L.

2014

Volltextzugriff (PDF)

The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil

Journal of adolescent health, 2011-11, Vol.49 (5), p.467-475

2011

Volltextzugriff (PDF)

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine (Gardasil®): A Review of its Use in the Prevention of Premalignant Genital Lesions, Genital Cancer and Genital Warts in Women

Drugs (New York, N.Y.), 2010-12, Vol.70 (18), p.2449-2474

2010

Volltextzugriff (PDF)

Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females

Vaccine, 2016-01, Vol.34 (1), p.172-178

2016

Volltextzugriff (PDF)

Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study

Japanese Journal of Infectious Diseases, 2019, Vol.72(5), pp.299-305

2019

Volltextzugriff (PDF)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males

Drugs (New York, N.Y.), 2011-03, Vol.71 (5), p.591-602

2011

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

ThemaVaccines

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Long-term study of a quadrivalent human papillomavirus vaccine

Indications and efficacy of the human papillomavirus vaccine

Prophylactic HPV vaccination: past, present, and future

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study

Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1–Infected Women

Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine

Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States

Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System

The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus

Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016)

Safety of quadrivalent human papillomavirus vaccine (Gardasil® ) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013

FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)

FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)

Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008–2011

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts

The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine (Gardasil®): A Review of its Use in the Prevention of Premalignant Genital Lesions, Genital Cancer and Genital Warts in Women

Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females

Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males

Aktive Filter

Suchergebnisse filtern